Astellas Pharma Inc

Price Chart

Risk-Adjusted Performance

Also Listed On

Astellas Pharma Inc (ALPMY) Price Performance

Astellas Pharma Inc (ALPMY) trades on United States in USD. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at $14.61, down 3.05% from the previous close.

Over the past year, ALPMY has traded between a low of $8.67 and a high of $16.56. The stock has gained 53.3% over this period. It is currently 11.8% below its 52-week high.

Astellas Pharma Inc has a market capitalization of $26.50B, with a price-to-earnings ratio of 33.32 and a dividend yield of 3.47%.

About Astellas Pharma Inc

Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.